Maggie Beller

October 21, 2021

Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors

Obsidian Therapeutics Appoints Maria Fardis, Ph.D., to Board of Directors Board expansion supports progression of engineered TIL therapies into clinical studies CAMBRIDGE, Mass., Oct. 21, 2021 […]
September 15, 2021

Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021

Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021 CAMBRIDGE, Mass., September 15, 2021 – Obsidian Therapeutics, […]
September 9, 2021

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

Obsidian Therapeutics Announces Closing of $115 Million Series B Financing Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies September 9, […]
May 4, 2021

Obsidian To Present Preclinical Data From cytoTIL15 Program at ASGCT

Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the 24th American Society of Gene and Cell Therapy Annual Meeting May 4, 2021, 08:00 AM […]
April 22, 2021

Vertex and Obsidian Therapeutics Establish Collaboration

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing April 22, 2021, 08:00 AM Eastern Time Multi-year strategic research collaboration leverages […]
November 18, 2020

Obsidian Therapeutics & MD Anderson Announce Strategic Collaboration

Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors Nov. 18, 2020, 08:30 […]
September 17, 2020

Obsidian Therapeutics Appoints Jan ter Meulen, M.D., Ph.D., as Chief Scientific Officer

Obsidian Therapeutics Appoints Jan ter Meulen, M.D., Ph.D., as Chief Scientific Officer Sept. 17, 2020, 08:00 AM Eastern Time CAMBRIDGE, Mass., Sept. 17, 2020 – Obsidian Therapeutics, Inc., […]
September 15, 2020

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate

Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate Sept. 15, 2020, 07:30 AM Eastern Time CAMBRIDGE, Mass., Sept. 15, 2020 – Obsidian Therapeutics, Inc., […]
September 3, 2020

Obsidian Therapeutics Appoints Rob Ross, M.D., to Board of Directors

Obsidian Therapeutics Appoints Rob Ross, M.D., to Board of Directors Board expansion supports ongoing development of cytoDRiVE™ programs and external collaborations Sept. 3, 2020, 08:00 AM […]